Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)

NCT07039110 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07039110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07039110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Recruiting
Start date
September 9, 2025
Completion date
March 31, 2028
Enrollment
700 (estimated)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis